This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543-51. DOI: 10.1016/j.jaci.2018.03.004.Search in Google Scholar
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600.Search in Google Scholar
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicenter, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-50. DOI: 10.1016/S0140-6736(19)31881-1.Search in Google Scholar
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595-605. DOI: 10.1016/j. jaci.2020.05.032.Search in Google Scholar
Han JK, Bachert C, Fokkens WJ, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141-53. DOI: 10.1016/S2213-2600(21)00097-7..Search in Google Scholar
Dzaman K, Rudnicka L, Rykowska A, et al. Challenges in implementing personalized medicine in Central and Eastern Europe. Front Genet. 2020;11:550.Search in Google Scholar
Tait Wojno ED, Monticelli LA. The dynamic nasal immune landscape in chronic rhinosinusitis. Curr Opin Immunol. 2022;74:47-54.Search in Google Scholar
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. DOI: 10.1038/s41591-018-0300-7.Search in Google Scholar
Orcid profile